Cue Biopharma (CUE) Debt Ratio (2022 - 2025)

Cue Biopharma (CUE) posted Debt Ratio of 0.02 for Q4 2025, down 68.66% sequentially from 0.05 in Q3 2025.

Cue Biopharma (CUE) Debt Ratio (2022 - 2025) Analysis & Trends

Cue Biopharma has reported Debt Ratio for 4 years, with the latest figure at 0.02 in Q4 2025.

Quarterly Debt Ratio changed N/A year-over-year to 0.02 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.02 (changed N/A YoY) and the FY2025 annual result came in at 0.02, changed N/A from the prior year.
Debt Ratio retreated to 0.02 in Q4 2025 per CUE's latest filing, from 0.05 in the prior quarter.
Over five years, Debt Ratio peaked at 0.15 in Q1 2025 and troughed at 0.01 in Q3 2022.
A 4-year average of 0.1 and a median of 0.12 in 2022 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2023 and 2025: Debt Ratio jumped 820.44% in 2023, then tumbled 56.89% in 2025.
Over 4 years, Debt Ratio stood at 0.11 in 2022, then gained by 21.16% to 0.13 in 2023, then decreased by 15.91% to 0.11 in 2024, then slumped by 85.37% to 0.02 in 2025.
According to Business Quant data, Debt Ratio over the past three periods registered 0.02, 0.05, and 0.06 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Cue Biopharma	152.56 Mn	135.14 Mn	-	0.03

Download Data